Abbott Diabetes Care
72
4
8
50
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.9%
5 terminated/withdrawn out of 72 trials
90.9%
+4.4% vs industry average
1%
1 trials in Phase 3/4
30%
15 of 50 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (72)
Glycemic Metrics and Patterns in People With and Without Prediabetes
Role: lead
FSL2 Post Approval Study for Pediatric and Young Adults Patients
Role: lead
Comparison Study of Blood Glucose Monitoring Systems in People With Diabetes
Role: lead
The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectiveness of AID Treatment
Role: collaborator
CGM Use in Adults With Type 2 Diabetes on Basal Insulin
Role: lead
Initiation of Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin, in Italy
Role: lead
CGM Use in Heart Failure
Role: collaborator
REMIssion of Type 2 Diabetes Between Intermittently Scanned Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring When Added to Low-calorie Meal Replacement and Diabetes Self-management Education
Role: collaborator
Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis
Role: collaborator
The FreeStyle Libre Enabled Reduction of A1c Through Effective Eating and Exercise Study
Role: collaborator
HbA1c Variation Study
Role: lead
Comparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes.
Role: collaborator
Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)
Role: collaborator
IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)
Role: collaborator
CGM Plus GEM in Prediabetes
Role: collaborator
T2 FSL2 Weight Loss
Role: lead
Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People With T2 Diabetes
Role: lead
Metabolic Wellness and CGM
Role: collaborator
Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring
Role: lead
Effect on HbA1c of the Initiation of CGM in Adults With Type 2 Diabetes Treated With Basal Insulin in Finland
Role: lead